Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a late clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific poster entitled: Comparative In Vitro Killing Kinetics of Ibezapolstat and Comparator Antibiotics in Clostridioides difficile and Vancomycin-resistant Enterococcus Co-Cultures was presented at the 9th International C. difficile Symposium held in Bled, Slovenia from September 8-10, 2026. The
This is the newest page. Registered accounts read further back.